Although pCR rates are lower for patients with ER+/HER2+ cancers following HER2 blockade with chemotherapy, the low pCR rates following chemotherapy-free approaches observed in PALTAN and several other trials suggest that chemotherapy remains a vital component for this group of patients. The gene discussed is ERBB2; the disease is cancer.